Zhong-Yi Dong

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 21

Top Topics

Small Cell Lung Cancer

Top Venues

Cancer research

Nature communications

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Jia-Run Lin, Duan-Duan Han, Wei Wei, Qin Zeng, Zi-Xuan Rong, Xue Bai, Yan-Pei Zhang, Jian Wang, Xiao-Ting Cai, Xu-Guang Rao, Si-Cong Ma, Zhong-Yi Dong
Regular Use of Aspirin and Statins Reduces the Risk of Cancer in Individuals with Systemic Inflammatory Diseases. Cancer research 84 (11) (2024)
Jia-Run Lin, Duan-Duan Han, Wei Wei, Qin Zeng, Zi-Xuan Rong, Xue Bai, Yan-Pei Zhang, Jian Wang, Xiao-Ting Cai, Xu-Guang Rao, Si-Cong Ma, Zhong-Yi Dong
Regular Use of Aspirin and Statins Reduces the Risk of Cancer in Individuals with Systemic Inflammatory Diseases. Cancer research 84 (11) (2024)
Jia-Run Lin, Duan-Duan Han, Wei Wei, Qin Zeng, Zi-Xuan Rong, Xue Bai, Yan-Pei Zhang, Jian Wang, Xiao-Ting Cai, Xu-Guang Rao, Si-Cong Ma, Zhong-Yi Dong
Regular use of aspirin and statins reduces the risk of cancer in individuals with systemic inflammatory diseases. Cancer research (2024)
Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, Xue-Jun Guo, Jia-Le Tan, Xiao-Ting Cai, Yan Lin, Xinghua Pan, De-Hua Wu, Xue Bai, Zhong-Yi Dong
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. Cancer research 83 (4) (2023)
Xue-Jun Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yan-Pei Zhang, Yu-Xiang Wen, Xue Bai, Jian Wang, Qiang John Fu, Ze-Qin Guo, Li-Li Long, Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong-Yi Dong, De-Hua Wu
Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC medicine 21 (1) (2023)
Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhen-Zhen Fan, Li-Juan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang, Xin-Ran Tang, Yu-Jie Zeng, Xinghua Pan, De-Hua Wu, Zhong-Yi Dong
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nature communications 14 (1) (2023)
Xue-Jun Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yan-Pei Zhang, Yu-Xiang Wen, Xue Bai, Jian Wang, Qiang John Fu, Ze-Qin Guo, Li-Li Long, Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong-Yi Dong, De-Hua Wu
Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC medicine 21 (1) (2023)
Xue-Jun Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yan-Pei Zhang, Yu-Xiang Wen, Xue Bai, Jian Wang, Qiang John Fu, Ze-Qin Guo, Li-Li Long, Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong-Yi Dong, De-Hua Wu
Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC medicine 21 (1) (2023)
Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhen-Zhen Fan, Li-Juan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang, Xin-Ran Tang, Yu-Jie Zeng, Xinghua Pan, De-Hua Wu, Zhong-Yi Dong
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nature communications 14 (1) (2023)
Xue Bai, Ze-Qin Guo, Yan-Pei Zhang, Zhen-Zhen Fan, Li-Juan Liu, Li Liu, Li-Li Long, Si-Cong Ma, Jian Wang, Yuan Fang, Xin-Ran Tang, Yu-Jie Zeng, Xinghua Pan, De-Hua Wu, Zhong-Yi Dong
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. Nature communications 14 (1) (2023)
Xue-Jun Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yan-Pei Zhang, Yu-Xiang Wen, Xue Bai, Jian Wang, Qiang John Fu, Ze-Qin Guo, Li-Li Long, Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong-Yi Dong, De-Hua Wu
Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC medicine 21 (1) (2023)
Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, Xue-Jun Guo, Jia-Le Tan, Xiao-Ting Cai, Yan Lin, Xinghua Pan, De-Hua Wu, Xue Bai, Zhong-Yi Dong
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. Cancer research 83 (4) (2023)
Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, Xue-Jun Guo, Jia-Le Tan, Xiao-Ting Cai, Yan Lin, Xinghua Pan, De-Hua Wu, Xue Bai, Zhong-Yi Dong
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. Cancer research 83 (4) (2023)
Xue-Jun Guo, Xiao-Ting Cai, Zi-Xuan Rong, Yan-Pei Zhang, Yu-Xiang Wen, Xue Bai, Jian Wang, Qiang John Fu, Ze-Qin Guo, Li-Li Long, Si-Cong Ma, Xin-Ran Tang, Li Liu, Jian Guan, Zhong-Yi Dong, De-Hua Wu
Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation. BMC medicine 21 (1) (2023)
Si-Cong Ma, Xue Bai, Xue-Jun Guo, Li Liu, Lu-Shan Xiao, Yan Lin, Jia-Le Tan, Xiao-Ting Cai, Yu-Xiang Wen, Hu Ma, Q John Fu, Meng-Xin Leng, Yan-Pei Zhang, Li-Li Long, Ze-Qin Guo, De-Hua Wu, Jian-Guo Zhou, Zhong-Yi Dong
Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice. BMC medicine 20 (1) (2022)
Li-Li Long, Si-Cong Ma, Ze-Qin Guo, Yan-Pei Zhang, Zhenzhen Fan, Li-Juan Liu, Li Liu, Duan-Duan Han, Meng-Xin Leng, Jian Wang, Xue-Jun Guo, Jia-Le Tan, Xiao-Ting Cai, Yan Lin, Xinghua Pan, De-Hua Wu, Xue Bai, Zhong-Yi Dong
PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer. Cancer research (2022)
Lu-Shan Xiao, Cheng-Yi Hu, Hao Cui, Rui-Ning Li, Chang Hong, Qi-Mei Li, Chao-Yi Huang, Zhong-Yi Dong, Hong-Bo Zhu, Li Liu
Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors. Cancer medicine (2022)
Shan Su, Mei-Feng Ye, Xiao-Ting Cai, Xue Bai, Zhi-Hao Huang, Si-Cong Ma, Jian-Jun Zou, Yu-Xiang Wen, Li-Juan Wu, Xue-Jun Guo, Xian-Lan Zhang, Wen-Chang Cen, Duo-Hua Su, Hui-Yi Huang, Zhong-Yi Dong
Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage. BMC medicine 19 (1) (2021)
Xue Bai, De-Hua Wu, Si-Cong Ma, Jian Wang, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuan-Hui Cao, He-San Luo, Yu-Han Chen, Hong-Bo Zhu, Hong-Hong Yan, Yi-Long Wu, Zhong-Yi Dong
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study Journal for immunotherapy of cancer 8 (1) (2021)
Wen-Jing Yin, Si-Cong Ma, Zhong-Yi Dong, Meng Xu, Wu Mao
Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy. Cancer management and research 13 (2021)
Si-Cong Ma, Xin-Ran Tang, Li-Li Long, Xue Bai, Jian-Guo Zhou, Zhi-Jiao Duan, Jian Wang, Qiang John Fu, Hong-Bo Zhu, Xue-Jun Guo, Yan-Pei Zhang, Ze-Qin Guo, De-Hua Wu, Zhong-Yi Dong
Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies. Oncoimmunology 10 (1) (2021)